The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...
MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback